<DOC>
	<DOCNO>NCT01005680</DOCNO>
	<brief_summary>The purpose study compare efficacy safety two different chemotherapy type first line treatment advance Non-Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Comparing Two Different Chemotherapy Types Chinese Patients With Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Present histologically proven cytological diagnosis nonsquamous nonsmall cell lung cancer ( NSCLC ) Stage IIIB IV . Participants must agree use reliable method birth control study 3 month follow last dose study drug . Female participant must pregnant . No prior systemic chemotherapy lung cancer . At least one unidimensionally measurable lesion meeting Response Evaluation Criteria Solid Tumors . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . Adequate organ function . Prior radiation therapy allow &lt; 25 % bone marrow . Signed informed consent document file . Estimated life expectancy great equal 12 week . Participant compliance geographic proximity allow adequate follow . Peripheral neuropathy great equal Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 . Inability comply protocol study procedure . A serious concomitant systemic disorder , opinion investigator , would compromise participant 's ability complete study . A serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV . Second primary malignancy clinically detectable time consideration study enrollment . Documented brain metastasis unless participant complete successful local therapy central nervous system metastases take corticosteroid least 4 week enrollment . Presence clinically significant thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry . Significant weight loss ( , great equal 10 % ) previous 6 week study entry . Concurrent administration antitumor therapy . Inability interrupt aspirin nonsteroidal antiinflammatory agent 5day period ( 8day period longacting agent , piroxicam ) . Inability unwillingness take folic acid vitamin B12 supplementation . Inability take corticosteroid . Pregnant breastfeeding . Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device ( study drug ) , concurrently enrol type medical research judge scientifically medically compatible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>